DFTX
NASDAQ HealthcareDefinium Therapeutics, Inc. - Common Shares
Biotechnology
Definium Therapeutics, Inc., a clinical biopharmaceutical company, develops novel product candidates to treat brain health disorders. The company's lead product candidates DT120, which is in phase 3 for the treatment of generalized anxiety disorder, major depressive disorder, and other brain health disorders; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc. and changed its name to Definium Therapeutics, Inc. in January 2026. Definium Therapeutics, Inc. is headquartered in New York, New York.
๐ Market Data
| Price | $21.70 |
|---|---|
| Volume | 1,402,255 |
| Market Cap | 2.37B |
| Beta | 2.560 |
| RSI (14-Day) | 46.6 |
| 200-Day MA | $14.10 |
| 50-Day MA | $19.65 |
| 52-Week High | $26.25 |
| 52-Week Low | $6.03 |
| Forward P/E | -12.58 |
| Price / Book | 6.45 |
๐ฏ Investment Strategy Scores
DFTX scores across each investment strategy. Higher is better for that strategy's goals.
๐ Strategy Interpretation
Best fit: ๐ Moon Shot (97/100) โ this strategy High growth potential (high beta + oversold).
Lowest fit among scored strategies: ๐ฐ Dividend Daddy (2/100). No single score is a buy or sell signal โ use multiple lenses together. Learn how to read these scores โ
๐ Learn More
Indicators on this page
Educational articles
Find DFTX in your text
Paste any article, transcript, or post โ the tool will extract DFTX and every other hidden ticker.
Disclaimer: This data is for educational and entertainment purposes only and does not constitute financial advice. Market data may be delayed. Always do your own research before making investment decisions.
Data last updated: 2026-05-01.